- US-listed companies
- Avidity Biosciences, Inc.
- Income statement
Avidity Biosciences, Inc. (RNAM) Income statement
Market cap
$11.3B
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Revenue | 7 | 9 | 9 | 10 | 11 | 19 |
| Revenue growth (%) | - | |||||
| Research & development | 38 | 101 | 150 | 191 | 304 | 559 |
| Operating margin (%) | ||||||
| Operating expenses | 51 | 127 | 188 | 245 | 390 | 765 |
| Operating income | -44 | -118 | -179 | -236 | -379 | -746 |
| Net income | -44 | -118 | -174 | -212 | -322 | -685 |
| Net income margin (%) | ||||||
| Earnings per share | - | - | -3.34 | -2.91 | -2.89 | -4.97 |
| Diluted EPS | - | - | -3.34 | -2.91 | -2.89 | -4.97 |